A Targeted Approach to the Complications of Targeted Therapy

J Thorac Oncol. 2019 Apr;14(4):577-579. doi: 10.1016/j.jtho.2018.12.034.

Authors

John A Mackintosh¹, Henry M Marshall², Kwun M Fong³

Affiliations

¹ Royal Brompton Hospital, London, United Kingdom.
² University of Queensland Thoracic Research Centre, Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, Australia.
³ University of Queensland Thoracic Research Centre, Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, Australia. Electronic address: kwun_fong@health.qld.gov.au.

PMID: 30922572
DOI: 10.1016/j.jtho.2018.12.034

No abstract available

Publication types

Editorial
Comment

MeSH terms

Crizotinib
Humans
Japan
Lung Diseases, Interstitial*
Lung Neoplasms*
Molecular Targeted Therapy
Receptor Protein-Tyrosine Kinases
Risk Factors

Substances

Crizotinib
Receptor Protein-Tyrosine Kinases